Lantern Pharma, Inc. LTRN 深 沪
已收盘 02-06 16:00:00 美东时间
2.64
+0.080
+3.13%
华盛通- 最 高2.6723
- 今 开2.59
- 成交量 4.55万股
- 最 低 2.575
- 昨 收 2.56
- 总市值 2952.69万
- 52周最高 5.7441
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 2.53
- 委 比 -53.06%
- 总股本 1118.44万
- 历史最高 24.84
- 量 比 0.63
- 振 幅 3.80%
- 历史最低 2.38
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India
The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with global biopharma
01-12 22:09
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
2025-11-13 20:06
Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the
2025-11-13 19:03
Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284 At 25th Annual Lymphoma, Leukemia & Myeloma Congress
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel differentiated synthetic
2025-10-28 20:51
快讯 | Lantern Pharma股价上涨9.5% 其抗癌药物达到早期试验目标后
Lantern Pharma Shares Rise 9.5% After Co's Cancer Drug Met Early-Stage Trial Go...
2025-09-16 22:16
Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies.Clinical benefit
2025-09-16 20:30
快讯 | Lantern Pharma的LP-184一期1a临床试验在多种晚期实体瘤中达到所有主要终点，具有稳健的安全性特征和令人鼓舞的抗肿瘤活性
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints ...
2025-09-16 20:29
Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform,
2025-09-03 21:47
Lantern Pharma shares are trading lower. The company reported Q2 financial results.
Lantern Pharma shares are trading lower. The company reported Q2 financial resu...
2025-08-14 23:52
